Scholar Rock Holding Corp

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Scholar Rock advances myostatin programs, eyes regulatory milestones in 2024

Scholar Rock's Q3 performance reflects progress in myostatin programs and expansion into cardiometabolic disorders, supported by strong financials and partnerships.
The company's focus on myostatin biology, promising results of apitegromab and SRK-439, and engagement with regulatory authorities position them for future success.
While facing challenges in statistical assumptions, patient variability, and therapy safety, Scholar Rock's deep understanding of myostatin presents opportunities for growth and innovation.

Scholar Rock excels in Q3 with SMA breakthrough and strong financial backing

Scholar Rock's Q3 performance showcases promising advancements in SMA treatment and strategic initiatives to drive future growth and commercial success.
The company's strong financial position, diverse pipeline, and focus on patient-centric care position them well for potential market leadership.
While facing challenges in regulatory approval and market competition, Scholar Rock's proactive approach and innovative drug candidates present significant opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Scholar Rock and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer.

Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -7.69% and -13.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q2 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the second quarter ended June 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs. “Scholar Rock has had significant momentum in the first half of the year with further demonstration of apitegromab's transformativ

Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11th, 2021 at 9:10 a.m. ET. A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Scholar Rock website at http://investors.s

Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that CEO Tony Kingsley has departed Scholar Rock and has also stepped down from the Board of Directors. Nagesh Mahanthappa, Ph.D., the founder and former chief executive of Scholar Rock has been appointed Interim CEO until a successor is named. Scholar Rock's Board of Direc

Scholar Rock Announces Leadership Change

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q2 Earnings Expected to Decline

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.

Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Jefferies Virtual Healthcare Conference on Wednesday, June 2nd, 2021 at 11:00 a.m. ET. Goldman Sachs Annual Global Healthcare Conference on Wednesday, June 9th, 2021 at 2:10 p.m. ET. BMO Biopha

Scholar Rock to Present at Upcoming Healthcare Conferences in June

The stock price of Scholar Rock (NASDAQ: SRRK) increased by over 8% pre-market. This is why it happened.

SRRK Stock Price: Over 8% Increase Pre-Market Explanation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock receives fast track designation from the FDA for Apitegromab for the treatment of patients with spinal muscular atrophy.

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a trials in progress poster presentation at the 2021 ASCO Annual Meeting, being held from June 4-8, 2021.

Scholar Rock to Present Trials in Progress Poster for SRK-181 DRAGON Phase 1 Clinical Trial at the American Society of Clinical Oncology Annual Meeting

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -10.14% and -29.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Scholar Rock Holding Corporation (SRRK) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent progress and upcoming milestones for its pipeline programs. Company Updates and Upcoming Milestones Apitegromab is a selective inhibitor of myostatin activation being developed as the potenti

Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that findings from its Phase 1 trial of apitemograb were published in the peer-reviewed journal Advances in Therapy.

Scholar Rock Announces Publication of Phase 1 Clinical Trial Data Evaluating Apitegromab in Healthy Volunteers in the Journal Advances in Therapy

Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q1 Earnings Expected to Decline

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,981,981 with an expiry of May 2034.

Scholar Rock Announces Issuance of U.S. Patent Broadly Relevant to Inhibitors of Myostatin Activation

Frequency Therapeutics

Solid Biosciences

These drugmaker stocks may have been hammered down to bargain-bin prices.

3 Beaten-Down Biotech Stocks: Can They Recover?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 from April 10 - 15.

Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting

Scholar Rock (NASDAQ: SRRK) shares dropped despite the company reporting positive 12-month data on spinal muscular atrophy (SMA) candidate apitegromab. The 12-month update was broadly in line with the six-month data that was announced in October last year.

Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy

Scholar Rock (NASDAQ: SRRK) has announced top-line data from the TOPAZ Phase 2 trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). In Cohort 1 (pooled population), the mean change from baseline in Revised Hammersmith Scale (RHS) score was a 0.3-point decline.

Scholar Rock Reports Apitegromab Data In Spinal Muscular Atrophy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced positive top-line data from the TOPAZ Phase 2 clinical trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). “These top-line 12-month data provide further support towards establishing apitegromab as a potential first muscle-

Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the publication of preclinical development data for SRK-181 in the peer-reviewed journal International Journal of Toxicology.

Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology

News for Scholar Rock Holding Corp Stock (SRRK)